Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Iterum Therapeutics

Nasdaq:ITRM
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ITRM
Nasdaq
$40M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Iterum Therapeutics has significant price volatility in the past 3 months.
ITRM Share Price and Events
7 Day Returns
-0.6%
NasdaqGM:ITRM
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-70.6%
NasdaqGM:ITRM
-2%
US Pharmaceuticals
-10%
US Market
ITRM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Iterum Therapeutics (ITRM) -0.6% 14% -37.6% -70.6% - -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • ITRM underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • ITRM underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Iterum Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Iterum Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Iterum Therapeutics.

NasdaqGM:ITRM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:ITRM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 6.5%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.629 (1 + (1- 12.5%) (52.18%))
0.944
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.944 * 6.51%)
7.88%

Discounted Cash Flow Calculation for NasdaqGM:ITRM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Iterum Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:ITRM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.88%)
2020 -50.80 Analyst x1 -47.09
2021 -67.70 Analyst x1 -58.17
2022 -40.60 Analyst x1 -32.33
2023 -0.40 Analyst x1 -0.30
2024 33.60 Analyst x1 22.99
2025 56.52 Est @ 68.22% 35.85
2026 83.81 Est @ 48.28% 49.28
2027 112.57 Est @ 34.32% 61.35
2028 140.19 Est @ 24.54% 70.82
2029 165.01 Est @ 17.7% 77.27
Present value of next 10 years cash flows $179.00
NasdaqGM:ITRM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $165.01 × (1 + 1.74%) ÷ (7.88% – 1.74%)
$2,733.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,733.09 ÷ (1 + 7.88%)10
$1,279.80
NasdaqGM:ITRM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $179.00 + $1,279.80
$1,458.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,458.80 / 14.87
$98.11
NasdaqGM:ITRM Discount to Share Price
Calculation Result
Value per share (USD) From above. $98.11
Current discount Discount to share price of $2.68
= -1 x ($2.68 - $98.11) / $98.11
97.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Iterum Therapeutics is available for.
Intrinsic value
>50%
Share price is $2.68 vs Future cash flow value of $98.11
Current Discount Checks
For Iterum Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Iterum Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Iterum Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Iterum Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Iterum Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ITRM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-7.10
NasdaqGM:ITRM Share Price ** NasdaqGM (2020-04-07) in USD $2.68
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Iterum Therapeutics.

NasdaqGM:ITRM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ITRM Share Price ÷ EPS (both in USD)

= 2.68 ÷ -7.10

-0.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Iterum Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Iterum Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Iterum Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:ITRM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
46.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Iterum Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Iterum Therapeutics's assets?
Raw Data
NasdaqGM:ITRM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-1.76
NasdaqGM:ITRM Share Price * NasdaqGM (2020-04-07) in USD $2.68
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:ITRM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ITRM Share Price ÷ Book Value per Share (both in USD)

= 2.68 ÷ -1.76

-1.52x

* Primary Listing of Iterum Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Iterum Therapeutics has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.
X
Value checks
We assess Iterum Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Iterum Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Iterum Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
46.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Iterum Therapeutics expected to grow at an attractive rate?
  • Iterum Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Iterum Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Iterum Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ITRM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ITRM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 46.5%
NasdaqGM:ITRM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 58.7%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ITRM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ITRM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 221 57 3
2023-12-31 106 -14 -8 5
2022-12-31 48 -48 -46 5
2021-12-31 12 -73 -68 5
2020-12-31 0 -49 -56 4
2020-04-08
NasdaqGM:ITRM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -79 -103
2019-09-30 0 -83 -104
2019-06-30 1 -85 -97
2019-03-31 1 -79 -85
2018-12-31 1 -76 -77
2018-09-30 1 -62 -62
2018-06-30 1 -40 -45
2018-03-31 1 -37 -36
2017-12-31 1 -31 -29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Iterum Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Iterum Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ITRM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Iterum Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ITRM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.54 2.41 0.67 2.00
2023-12-31 -0.14 0.08 -0.26 3.00
2022-12-31 -0.97 -0.50 -1.74 3.00
2021-12-31 -1.38 -0.82 -2.08 3.00
2020-12-31 -3.33 -2.43 -4.01 3.00
2020-04-08
NasdaqGM:ITRM Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -7.10
2019-09-30 -7.30
2019-06-30 -7.05
2019-03-31 -6.97
2018-12-31 -8.82
2018-09-30 -11.49
2018-06-30 -20.79
2018-03-31 -172.09
2017-12-31 -170.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Iterum Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Iterum Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Iterum Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Iterum Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Iterum Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Iterum Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Iterum Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Iterum Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Iterum Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Iterum Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ITRM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.04 -103.13 11.28 90.77
2019-09-30 0.28 -103.75 11.71 91.35
2019-06-30 0.53 -97.38 11.44 85.87
2019-03-31 0.72 -85.49 10.38 75.16
2018-12-31 0.87 -77.06 8.78 68.65
2018-09-30 0.98 -61.92 7.37 55.43
2018-06-30 0.88 -45.18 5.73 40.28
2018-03-31 0.70 -35.72 4.97 31.84
2017-12-31 0.51 -29.41 4.46 25.50
2016-12-31 -13.46 3.26 10.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Iterum Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Iterum Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Iterum Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Iterum Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Iterum Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Iterum Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Iterum Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Iterum Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Iterum Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Iterum Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Iterum Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Iterum Therapeutics Company Filings, last reported 3 months ago.

NasdaqGM:ITRM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -26.24 13.43 5.94
2019-09-30 -3.10 14.34 29.91
2019-06-30 24.58 14.27 52.02
2019-03-31 51.63 14.20 70.47
2018-12-31 71.62 14.10 85.51
2018-09-30 94.10 14.54 109.62
2018-06-30 118.53 14.51 136.47
2018-03-31 59.73 0.00 60.64
2017-12-31 39.55 0.00 40.56
2016-12-31 22.70 0.00 25.21
  • Iterum Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Iterum Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Iterum Therapeutics has less than a year of cash runway based on current free cash flow.
  • Iterum Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 47.2% each year.
X
Financial health checks
We assess Iterum Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Iterum Therapeutics has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Iterum Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Iterum Therapeutics dividends.
If you bought $2,000 of Iterum Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Iterum Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Iterum Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ITRM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ITRM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Iterum Therapeutics has not reported any payouts.
  • Unable to verify if Iterum Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Iterum Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Iterum Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Iterum Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Iterum Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Iterum Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Iterum Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Corey Fishman
COMPENSATION $1,392,031
AGE 54
TENURE AS CEO 4.4 years
CEO Bio

Mr. Corey N. Fishman has been the Chief Executive Officer of Iterum Therapeutics Ltd since November 2015 and serves as its President. Mr. Fishman serves as Chief Executive Officer at Iterum Therapeutics US Limited. He served as the Chief Operating Officer and Chief Financial Officer of Durata Therapeutics, Inc. since August 15, 2010 and June 2012 until 2015 respectively and serves as its Principal Accounting Officer. Mr. Fishman served as Chief Operating Officer of Vicuron Pharmaceuticals Inc. He served as Secretary and Treasurer of Durata Therapeutics, Inc. He served as Chief Financial Officer of GANIC Pharmaceuticals Inc. until June 2010. He served as Executive Vice President of Finance and Chief Financial Officer of Meda Pharmaceuticals, Inc. since May 1, 2006 until March 2008 and served as its Senior Vice President of Finance & Operations from 2005 to May 1, 2006. He has over 18 years of experience in finance, business development and operations within the pharmaceutical industry. Mr. Fishman began his career in business analysis for LyphoMed, Inc. From 1990 to 1994, Mr. Fishman worked at a start-up company where he was instrumental in Medpointe Inc.'s spin off, initial public offering and capital formation activities. In 1994, he joined Searle Pharmaceuticals and held positions in US operations as well as in its mergers and acquisitions organization. In 1996, he was promoted by Searle's parent, Monsanto Co., to a senior position in the parent's global financial planning and analysis organization. Two years later, Mr. Fishman rejoined Searle within its Asia Pacific/Latin America/Canada region where, among a variety of responsibilities, he participated in the planning and launch of Celebrex in a number of non-US markets. Following the merger of Searle/Monsanto with Pharmacia Corp., he served as an Executive Director of Business Operations for the Latin American region. He joined MedPointe in 2002 as an Executive Director of Commercial Operations. Six months after joining Medpointe Inc, he was promoted to Vice President-Commercial Operations. He serves as Director of Iterum Therapeutics Ltd. He has been a Director of Momenta Pharmaceuticals Inc since September 22, 2016. Mr. Fishman received his BA in economics from the University of Illinois and his Masters in Management from the Krannert School of Management at Purdue University.

CEO Compensation
  • Corey's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Corey's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Iterum Therapeutics management team in years:

4.4
Average Tenure
54
Average Age
  • The tenure for the Iterum Therapeutics management team is about average.
Management Team

Corey Fishman

TITLE
President
COMPENSATION
$1M
AGE
54
TENURE
4.4 yrs

Judy Matthews

TITLE
Chief Financial Officer
COMPENSATION
$565K
AGE
49
TENURE
4.4 yrs

Mike Dunne

TITLE
Chief Scientific Officer
COMPENSATION
$883K
AGE
59
TENURE
4.4 yrs

Ben Pe

TITLE
Vice President of Operations
TENURE
5.3 yrs

Tom Loughman

TITLE
VP & CMC Head

Louise Barrett

TITLE
Secretary
Board of Directors Tenure

Average tenure and age of the Iterum Therapeutics board of directors in years:

3.3
Average Tenure
54
Average Age
  • The tenure for the Iterum Therapeutics board of directors is about average.
Board of Directors

Brent K. Ahrens

TITLE
Independent Interim Chairman
COMPENSATION
$123K
AGE
56
TENURE
0.8 yrs

Corey Fishman

TITLE
President
COMPENSATION
$1M
AGE
54

Ron Hunt

TITLE
Independent Director
COMPENSATION
$131K
AGE
54
TENURE
4.4 yrs

David Kelly

TITLE
Independent Director
COMPENSATION
$139K
AGE
58
TENURE
3.7 yrs

Patrick Heron

TITLE
Independent Director
COMPENSATION
$119K
AGE
49
TENURE
4.4 yrs

Mark Chin

TITLE
Independent Director
COMPENSATION
$129K
AGE
37
TENURE
2.9 yrs

Mohammed Shahzad Malik

TITLE
Independent Director
COMPENSATION
$125K
AGE
52
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Iterum Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Iterum Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did Changing Sentiment Drive Iterum Therapeutics's (NASDAQ:ITRM) Share Price Down A Worrying 51%?

While not a mind-blowing move, it is good to see that the Iterum Therapeutics plc (NASDAQ:ITRM) share price has gained 12% in the last three months. … A Different Perspective While Iterum Therapeutics shareholders are down 51% for the year, the market itself is up 3.4%. … It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at.

Simply Wall St -

Are Insiders Buying Iterum Therapeutics plc (NASDAQ:ITRM) Stock?

So before you buy or sell Iterum Therapeutics plc (NASDAQ:ITRM), you may well want to know whether insiders have been buying or selling. … The Last 12 Months Of Insider Transactions At Iterum Therapeutics. … Overall, Iterum Therapeutics insiders were net buyers last year

Simply Wall St -

What Investors Should Know About Iterum Therapeutics plc's (NASDAQ:ITRM) Financial Strength

Investors are always looking for growth in small-cap stocks like Iterum Therapeutics plc (NASDAQ:ITRM), with a market cap of US$76m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

How Many Iterum Therapeutics plc (NASDAQ:ITRM) Shares Do Institutions Own?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Iterum Therapeutics is not a large company by global standards. … institutions own shares in the company.

Simply Wall St -

Do You Know Who Else Invests In Iterum Therapeutics plc (NASDAQ:ITRM)?

Today, I will be analyzing Iterum Therapeutics plc’s (NASDAQ:ITRM) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure of a company has been found to affect share performance over time. … It also impacts the trading environment of company shares, which is more of a concern for short-term investors.

Simply Wall St -

Iterum Therapeutics plc's (NASDAQ:ITRM) Path To Profitability

Iterum Therapeutics plc's (NASDAQ:ITRM):. … Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. … The US$169.05m market-cap posted a loss in its most recent financial year of -US$29.41m and a latest trailing-twelve-month loss of -US$35.71m leading to an even wider gap between loss and breakeven?

Simply Wall St -

Company Info

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.

Details
Name: Iterum Therapeutics plc
ITRM
Exchange: NasdaqGM
Founded: 2015
$39,774,502
14,868,973
Website: http://www.iterumtx.com
Address: Iterum Therapeutics plc
Harcourt Centre,
Block 2, Floor 3,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ITRM Ordinary Shares Nasdaq Global Market US USD 25. May 2018
Number of employees
Current staff
Staff numbers
44
Iterum Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 08:30
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.